Your browser doesn't support javascript.
loading
Apathy in presymptomatic genetic frontotemporal dementia predicts cognitive decline and is driven by structural brain changes.
Malpetti, Maura; Jones, P Simon; Tsvetanov, Kamen A; Rittman, Timothy; van Swieten, John C; Borroni, Barbara; Sanchez-Valle, Raquel; Moreno, Fermin; Laforce, Robert; Graff, Caroline; Synofzik, Matthis; Galimberti, Daniela; Masellis, Mario; Tartaglia, Maria Carmela; Finger, Elizabeth; Vandenberghe, Rik; de Mendonça, Alexandre; Tagliavini, Fabrizio; Santana, Isabel; Ducharme, Simon; Butler, Chris R; Gerhard, Alexander; Levin, Johannes; Danek, Adrian; Otto, Markus; Frisoni, Giovanni B; Ghidoni, Roberta; Sorbi, Sandro; Heller, Carolin; Todd, Emily G; Bocchetta, Martina; Cash, David M; Convery, Rhian S; Peakman, Georgia; Moore, Katrina M; Rohrer, Jonathan D; Kievit, Rogier A; Rowe, James B.
Afiliação
  • Malpetti M; Department of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
  • Jones PS; Department of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
  • Tsvetanov KA; Department of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
  • Rittman T; Department of Clinical Neurosciences, Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK.
  • van Swieten JC; Department of Neurology, Erasmus Medical Centre, Rotterdam, Netherlands.
  • Borroni B; Department of Clinical and Experimental Sciences, Centre for Neurodegenerative Disorders, University of Brescia, Brescia, Italy.
  • Sanchez-Valle R; Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacións Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain.
  • Moreno F; Department of Neurology, Cognitive Disorders Unit, Donostia Universitary Hospital, San Sebastian, Spain.
  • Laforce R; Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain.
  • Graff C; Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, Faculté de Médecine, Université Laval, Québec, Canada.
  • Synofzik M; Department of Neurobiology Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Bioclinicum, Karolinska Institutet, Solna, Sweden.
  • Galimberti D; Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital, Solna, Sweden.
  • Masellis M; Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Tübingen, Germany.
  • Tartaglia MC; Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany.
  • Finger E; Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy.
  • Vandenberghe R; Centro Dino Ferrari, University of Milan, Milan, Italy.
  • de Mendonça A; Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada.
  • Tagliavini F; Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, Ontario, Canada.
  • Santana I; Department of Clinical Neurological Sciences, University of Western Ontario, London, Ontario, Canada.
  • Ducharme S; Department of Neurosciences, Laboratory for Cognitive Neurology, KU Leuven, Leuven, Belgium.
  • Butler CR; Neurology Service, University Hospitals Leuven, Leuven, Belgium.
  • Gerhard A; KU Leuven, Leuven Brain Institute, Leuven, Belgium.
  • Levin J; Faculty of Medicine, University of Lisbon, Lisbon, Portugal.
  • Danek A; Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy.
  • Otto M; University Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
  • Frisoni GB; Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
  • Ghidoni R; Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Québec, Canada.
  • Sorbi S; McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Québec, Canada.
  • Heller C; Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK.
  • Todd EG; Division of Neuroscience and Experimental Psychology, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK.
  • Bocchetta M; Departments of Geriatric Medicine and Nuclear Medicine, University of Duisburg- Essen, Duisburg, Germany.
  • Cash DM; Department of Neurology, Ludwig-Maximilians Universität München, Munich, Germany.
  • Convery RS; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.
  • Peakman G; Munich Cluster of Systems Neurology (SyNergy), Munich, Germany.
  • Moore KM; Department of Neurology, Ludwig-Maximilians Universität München, Munich, Germany.
  • Rohrer JD; Department of Neurology, University of Ulm, Ulm, Germany.
  • Kievit RA; IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
  • Rowe JB; Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.
Alzheimers Dement ; 17(6): 969-983, 2021 06.
Article em En | MEDLINE | ID: mdl-33316852
ABSTRACT

INTRODUCTION:

Apathy adversely affects prognosis and survival of patients with frontotemporal dementia (FTD). We test whether apathy develops in presymptomatic genetic FTD, and is associated with cognitive decline and brain atrophy.

METHODS:

Presymptomatic carriers of MAPT, GRN or C9orf72 mutations (N = 304), and relatives without mutations (N = 296) underwent clinical assessments and MRI at baseline, and annually for 2 years. Longitudinal changes in apathy, cognition, gray matter volumes, and their relationships were analyzed with latent growth curve modeling.

RESULTS:

Apathy severity increased over time in presymptomatic carriers, but not in non-carriers. In presymptomatic carriers, baseline apathy predicted cognitive decline over two years, but not vice versa. Apathy progression was associated with baseline low gray matter volume in frontal and cingulate regions.

DISCUSSION:

Apathy is an early marker of FTD-related changes and predicts a subsequent subclinical deterioration of cognition before dementia onset. Apathy may be a modifiable factor in those at risk of FTD.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Demência Frontotemporal / Apatia / Sintomas Prodrômicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Alzheimers Dement Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Encéfalo / Demência Frontotemporal / Apatia / Sintomas Prodrômicos Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged Idioma: En Revista: Alzheimers Dement Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Reino Unido